Q-omics provides the consensus-scored PPIAL4C profile across patient tissues and cancer cell-line models. PPIAL4C expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PPIAL4C is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, PPIAL4C RNA expression shows 6,923 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where PPIAL4C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAL4C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAL4C survival associations across molecular data types. PPIAL4C RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAL4C RNA expression–survival associations across cancer types. High PPIAL4C expression shows unfavorable associations in KIRP, ACC, HNSC, LIHC, MESO and GBM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for PPIAL4C RNA expression.
This table summarizes PPIAL4C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAL4C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAL4C shows lower tumor expression in COAD and higher tumor expression in BLCA, HNSC, LIHC, KIRC and BRCA. The BLCA box plot shows higher PPIAL4C RNA expression in tumor versus normal tissue (log2 FC = +0.170, t-test p < 0.001).
This table shows molecular features associated with PPIAL4C in patient tissues and cancer cell lines. In patient samples, PPIAL4C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPIAL4C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
